{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:52:48Z","timestamp":1778122368395,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"name":"NIH","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["IRG-21-145-25"],"award-info":[{"award-number":["IRG-21-145-25"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Team Science Award from the Moffitt Cancer Center Quantitative Science Program"},{"name":"Moffitt Cancer Center Department of Biostatistics and Bioinformatics Pilot Award"},{"name":"Florida Department of Health Live Like Bella Pediatric Research Initiative","award":["23L10"],"award-info":[{"award-number":["23L10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pathway-level survival analysis offers the opportunity to examine molecular pathways and immune signatures that influence patient outcomes. However, available survival analysis algorithms are limited in pathway-level function and lack a streamlined analytical process. Here we present a comprehensive pathway-level survival analysis suite, PATH-SURVEYOR, which includes a Shiny user interface with extensive features for systematic exploration of pathways and covariates in a Cox proportional-hazard model. Moreover, our framework offers an integrative strategy for performing Hazard Ratio ranked Gene Set Enrichment Analysis and pathway clustering. As an example, we applied our tool in a combined cohort of melanoma patients treated with checkpoint inhibition (ICI) and identified several immune populations and biomarkers predictive of ICI efficacy. We also analyzed gene expression data of pediatric acute myeloid leukemia (AML) and performed an inverse association of drug targets with the patient\u2019s clinical endpoint. Our analysis derived several drug targets in high-risk KMT2A-fusion-positive patients, which were then validated in AML cell lines in the Genomics of Drug Sensitivity database. Altogether, the tool offers a comprehensive suite for pathway-level survival analysis and a user interface for exploring drug targets, molecular features, and immune populations at different resolutions.<\/jats:p>","DOI":"10.1186\/s12859-023-05393-y","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:02:29Z","timestamp":1687932149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing"],"prefix":"10.1186","volume":"24","author":[{"given":"Alyssa N.","family":"Obermayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darwin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Nobles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiang","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aik-Choon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Ann","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Eschrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung-tsa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy I.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"issue":"W1","key":"5393_CR1","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-97.","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"5393_CR2","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5393_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"5393_CR4","doi-asserted-by":"crossref","unstructured":"Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2005;33(Database issue):D428\u2013432.","DOI":"10.1093\/nar\/gki072"},{"issue":"6","key":"5393_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"key":"5393_CR6","doi-asserted-by":"crossref","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437\u201352.","DOI":"10.1016\/j.cell.2017.10.049"},{"issue":"D1","key":"5393_CR7","doi-asserted-by":"publisher","first-page":"D721","DOI":"10.1093\/nar\/gky900","volume":"47","author":"X Zhang","year":"2019","unstructured":"Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C, Luo T, Xu L, Liao G, Yan M, et al. Cell marker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2019;47(D1):D721\u20138.","journal-title":"Nucleic Acids Res"},{"key":"5393_CR8","doi-asserted-by":"crossref","unstructured":"Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat. 2007; 1(1):107\u2013129.","DOI":"10.1214\/07-AOAS101"},{"key":"5393_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/1471-2105-6-225","volume":"6","author":"J Tomfohr","year":"2005","unstructured":"Tomfohr J, Lu J, Kepler TB. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinform. 2005;6:225.","journal-title":"BMC Bioinform"},{"key":"5393_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"issue":"7269","key":"5393_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108\u201312.","journal-title":"Nature"},{"issue":"7279","key":"5393_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7279):318\u201325.","journal-title":"Nature"},{"issue":"8","key":"5393_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.3593","volume":"48","author":"MJ Alvarez","year":"2016","unstructured":"Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, Califano A. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat Genet. 2016;48(8):838\u201347.","journal-title":"Nat Genet"},{"issue":"7708","key":"5393_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0177-0","volume":"558","author":"X Du","year":"2018","unstructured":"Du X, Wen J, Wang Y, Karmaus PWF, Khatamian A, Tan H, Li Y, Guy C, Nguyen TM, Dhungana Y, et al. Hippo\/Mst signalling couples metabolic state and immune function of CD8alpha(+) dendritic cells. Nature. 2018;558(7708):141\u20135.","journal-title":"Nature"},{"key":"5393_CR15","doi-asserted-by":"crossref","unstructured":"Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, et al. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022.","DOI":"10.1016\/j.ccell.2022.08.016"},{"issue":"1","key":"5393_CR16","doi-asserted-by":"publisher","first-page":"10258","DOI":"10.1038\/s41598-020-66986-8","volume":"10","author":"M Yi","year":"2020","unstructured":"Yi M, Nissley DV, McCormick F, Stephens RM. ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep. 2020;10(1):10258.","journal-title":"Sci Rep"},{"issue":"3","key":"5393_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2(3):284\u201399.","journal-title":"Nat Cancer"},{"issue":"10","key":"5393_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.15252\/emmm.201404208","volume":"6","author":"TZ Tan","year":"2014","unstructured":"Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014;6(10):1279\u201393.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"5393_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"key":"5393_CR20","doi-asserted-by":"crossref","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","DOI":"10.1093\/nar\/gkaa407"},{"key":"5393_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L, D\u2019Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017;5:18.","journal-title":"J Immunother Cancer"},{"key":"5393_CR22","doi-asserted-by":"crossref","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity 2018; 48(4):812\u201330.","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"5393_CR23","doi-asserted-by":"crossref","unstructured":"Coleman S, Xie M, Tarhini AA, Tan AC. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Mol Carcinog. 2022.","DOI":"10.1002\/mc.23442"},{"issue":"7791","key":"5393_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556\u201360.","journal-title":"Nature"},{"key":"5393_CR25","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/ncomms16022","volume":"8","author":"B Chen","year":"2017","unstructured":"Chen B, Ma L, Paik H, Sirota M, Wei W, Chua MS, So S, Butte AJ. Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat Commun. 2017;8:16022.","journal-title":"Nat Commun"},{"issue":"7","key":"5393_CR26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group. Haematologica. 2020;105(7):1879\u201386.","journal-title":"Haematologica"},{"issue":"1","key":"5393_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3324\/haematol.11666","volume":"93","author":"E Colado","year":"2008","unstructured":"Colado E, Alvarez-Fernandez S, Maiso P, Martin-Sanchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica. 2008;93(1):57\u201366.","journal-title":"Haematologica"},{"issue":"8","key":"5393_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649\u201358.","journal-title":"Neoplasia"},{"issue":"7","key":"5393_CR29","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A Lanczky","year":"2021","unstructured":"Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633.","journal-title":"J Med Internet Res"},{"issue":"1","key":"5393_CR30","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1038\/s41598-022-06841-0","volume":"12","author":"B Dwivedi","year":"2022","unstructured":"Dwivedi B, Mumme H, Satpathy S, Bhasin SS, Bhasin M. Survival genie, a web platform for survival analysis across pediatric and adult cancers. Sci Rep. 2022;12(1):3069.","journal-title":"Sci Rep"},{"key":"5393_CR31","doi-asserted-by":"crossref","unstructured":"Borcherding N, Bormann NL, Voigt AP, Zhang W. TRGAted: a web tool for survival analysis using protein data in the Cancer Genome Atlas. F1000Res 2018;7:1235.","DOI":"10.12688\/f1000research.15789.2"},{"key":"5393_CR32","doi-asserted-by":"crossref","unstructured":"Rupji M, Zhang X, Kowalski J. CASAS: cancer survival analysis suite, a web based application. F1000Res 2017;6:919.","DOI":"10.12688\/f1000research.11830.1"},{"issue":"5","key":"5393_CR33","doi-asserted-by":"publisher","first-page":"e16084","DOI":"10.2196\/16084","volume":"22","author":"K Pak","year":"2020","unstructured":"Pak K, Oh SO, Goh TS, Heo HJ, Han ME, Jeong DC, Lee CS, Sun H, Kang J, Choi S, et al. A user-friendly, web-based integrative tool (ESurv) for survival analysis: development and validation study. J Med Internet Res. 2020;22(5):e16084.","journal-title":"J Med Internet Res"},{"key":"5393_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020;2120:223\u201332.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"5393_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"5393_CR36","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"1","key":"5393_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.","journal-title":"Genome Biol"},{"key":"5393_CR38","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34(2):187.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"issue":"5\u20136","key":"5393_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/bfgp\/elq021","volume":"9","author":"MN Davies","year":"2010","unstructured":"Davies MN, Meaburn EL, Schalkwyk LC. Gene set enrichment; a problem of pathways. Brief Funct Genomics. 2010;9(5\u20136):385\u201390.","journal-title":"Brief Funct Genomics"},{"key":"5393_CR40","doi-asserted-by":"crossref","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934\u201349.","DOI":"10.1016\/j.cell.2017.09.028"},{"issue":"1","key":"5393_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"6257","key":"5393_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311.","journal-title":"Science"},{"issue":"12","key":"5393_CR43","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"key":"5393_CR44","doi-asserted-by":"crossref","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell 2019; 35(2):238\u201355.","DOI":"10.1016\/j.ccell.2019.01.003"},{"issue":"12","key":"5393_CR45","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351.","journal-title":"Lancet Oncol"},{"issue":"2","key":"5393_CR46","doi-asserted-by":"publisher","first-page":"e1231291","DOI":"10.1080\/2162402X.2016.1231291","volume":"6","author":"AA Tarhini","year":"2017","unstructured":"Tarhini AA, Lin Y, Lin HM, Vallabhaneni P, Sander C, LaFramboise W, Hamieh L. Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncoimmunology. 2017;6(2):e1231291.","journal-title":"Oncoimmunology"},{"issue":"24","key":"5393_CR47","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1093\/bioinformatics\/btz446","volume":"35","author":"O Dereli","year":"2019","unstructured":"Dereli O, Oguz C, Gonen M. Path2Surv: pathway\/gene set-based survival analysis using multiple kernel learning. Bioinformatics. 2019;35(24):5137\u201345.","journal-title":"Bioinformatics"},{"issue":"3","key":"5393_CR48","doi-asserted-by":"publisher","first-page":"e1010020","DOI":"10.1371\/journal.pcbi.1010020","volume":"18","author":"GS Jeuken","year":"2022","unstructured":"Jeuken GS, Tobin NP, Kall L. Survival analysis of pathway activity as a prognostic determinant in breast cancer. PLoS Comput Biol. 2022;18(3):e1010020.","journal-title":"PLoS Comput Biol"},{"key":"5393_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.12688\/hrbopenres.13476.1","volume":"5","author":"L King","year":"2022","unstructured":"King L, Flaus A, Coughlan S, Holian E, Golden A. GNOSIS: an R Shiny app supporting cancer genomics survival analysis with cBioPortal. HRB Open Res. 2022;5:8.","journal-title":"HRB Open Res"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05393-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-023-05393-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05393-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:04:53Z","timestamp":1687932293000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-023-05393-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5393"],"URL":"https:\/\/doi.org\/10.1186\/s12859-023-05393-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"28 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TIS, AO, and DTC report a provisional patent application for the PATH-SURVEYOR software. SAE reports intellectual property (RSI) and stock in Cvergenx. AT reports grants from Bristol Myers Squib, grants from Genentech-Roche, grants from Regeneron, grants from Sanofi-Genzyme, grants from Nektar, grants from Clinigen, grants from Merck, grants from Acrotech, grants from Pfizer, grants from Checkmate, grants from OncoSec, personal fees from Bristol Myers Squibb, personal fees from Merck, personal fees from Easai, personal fees from Instil Bio, personal fees from Clinigin, personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Novartis, personal fees from Partner Therapeutics, personal fees from Genentech\/Roche, personal fees from BioNTech, outside the submitted work. DC, GN, MT, ACT, GDG, XW, PR, and SM declare no other conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}